flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Long-term of in obesity and cardiovascular disease in the SELECT flow trial semaglutide kidney outcomes

Inhaltsverzeichnis 1

The better question is: Can newer weight-loss treatments help people lose fat while protecting lean muscle, strength, and long-term metabolic health

By activating the GLP-1 receptors in the body, Ozempic helps to suppress appetite and reduce food cravings

HUBERMAN: And in addition to wanting to teach you about some of the biology of these peptides and how they work and what they're designed to do, as well as some of their potential therapeutic benefits under the right conditions, again, working with a really good board-certified physician and making sure that the sourcing is really clean

Individuals who may be at greater risk include: Those with a pre-existing diagnosis of osteoarthritis, rheumatoid arthritis, or other inflammatory joint conditions Patients with obesity-related joint loading, particularly affecting the knees, hips, and lower back Older adults, in whom musculoskeletal complaints are more prevalent at baseline Individuals experiencing rapid weight loss, which may transiently alter joint mechanics and gait, particularly in the lower limbs this is a theoretical consideration based on general musculoskeletal principles rather than retatrutide-specific evidence Significant weight reduction one of retatrutide's primary therapeutic effects is generally associated with reduced mechanical load on weight-bearing joints , which may improve joint symptoms over time in individuals with obesity-related arthropathy

It supports both physical and cognitive performance by improving energy efficiency in the body